Status:

COMPLETED

Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain

Lead Sponsor:

Novartis

Conditions:

Grade I/II Ankle Sprain

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The main purpose of this trial is to compare the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice (b.i.d) or three times a day (t.i.d.) with placebo in the treatment of acute ank...

Eligibility Criteria

Inclusion

  • 1\. Acute sprain of the lateral ankle, Grade I-II .

Exclusion

  • Any concurrent injury affecting the lower extremities that is painful at rest or on movement, or could affect the mobilization of the patient.
  • Topical analgesic or anti-inflammatory treatment over the previous month in the area to be treated.

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2009

Estimated Enrollment :

242 Patients enrolled

Trial Details

Trial ID

NCT00955513

Start Date

July 1 2009

End Date

December 1 2009

Last Update

April 20 2012

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Novartis Investigative Site

Cologne, Germany

2

Novartis Investigative Site

Essen, Germany

3

Novartis Investigative Site

Gilching, Germany

4

Novartis Investigative Site

Grünwald, Germany